Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration

HIV Medicine

Volumn 14, Issue 10, 2013, Pages 633-638

  Bickel, M ^a   Khaykin, P ^a   Stephan, C ^a   Schmidt, K ^a   Buettner, M ^b   Amann, K ^b   Lutz, T ^c   Gute, P ^c   Haberl, A ^a   Geiger, H ^a   Brodt, Hr ^a   Jung, O ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Infektiologikum   (Germany)

Author keywords

Acute kidney injury; Drug drug interaction; Fanconi syndrome; HIV; Nonsteroidal anti inflammatory drugs; Tenofovir

Indexed keywords

ALLOPURINOL; ATAZANAVIR; COTRIMOXAZOLE; CREATININE; DICLOFENAC; MESALAZINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHORUS; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ACUTE KIDNEY FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOPHOSPHATEMIA; KIDNEY BIOPSY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ACUTE KIDNEY INJURY; DRUG-DRUG INTERACTION; FANCONI SYNDROME; HIV; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; TENOFOVIR;

ACUTE KIDNEY INJURY; ADENINE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG INTERACTIONS; FANCONI SYNDROME; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES;

EID: 84885470831     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12072     Document Type: Article

References (32)

1. Franceschini N, Napravnik S, Eron JJ, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67: 1526-1531.
2. Ibrahim F, Naftalin C, Cheserem E etal. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS 2010; 24: 2239-2244.
3. Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA. HIV care and the incidence of acute renal failure. Clin Infect Dis 2008; 47: 242-249.
4. Kalim S, Szczech LA, Wyatt CM. Acute kidney injury in HIV-infected patients. Semin Nephrol 2008; 28: 556-562.
5. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD etal. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
6. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18: 541-546.
7. Mocroft A, Kirk O, Gatell J etal. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 1119-1127.
8. Mocroft A, Kirk O, Reiss P etal.; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678.
9. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-290.
10. Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 2012; 8: 433-448.
11. Thompson MA, Aberg JA, Cahn P etal.; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
12. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-1198.
13. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341-346.
14. McMorran M. Tenofovir (viread) and NSAIDs: acute renal failure. Can Adver React Newslett 2006; 16: 1-2.
15. Bpharm SM, Talbot A, Trottier B. Acute renal failure in four HIV-infected patients: potential association with tenofovir and nonsteroidal anti-inflammatory drugs. Can J Infect Dis Med Microbiol 2008; 19: 75-76.
16. Madeddu G, Bonfanti P, De Socio GV etal.; CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother 2008; 62: 6-11.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266.
19. Mehta RL, Kellum JA, Shah SV etal.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
20. Murray MD, Brater DC. Effects of NSAIDs on the kidney. Prog Drug Res 1997; 49: 155-171.
21. Hasse B, Ledergerber B, Furrer H etal.; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130-1139.
22. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
23. Lopes JA, Melo MJ, Viegas A etal. Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrol Dial Transplant 2011; 26: 3888-3894.
24. Bagshaw SM, Laupland KB, Doig CJ etal. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9: R700-R709.
25. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB etal. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
26. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936.
27. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
28. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20: 561-565.
29. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78: 478-485.
30. Nelson MR, Katlama C, Montaner JS etal. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21: 1273-1281.
31. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction. Clin Nephrol 2009; 71: 567-570.
32. Bam R, Yant S, Cihla T. Tenofovir alafenamide (GS-7340) is not a substrate for renal organic anion transporters (OAT) and does not exhibit OAT-dependent cytotoxicity. Abstract 540; Conference on Retroviruses and Opportunistic Infections (CROI); Atlanta, Georgia, USA, 2013.